Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of TQB2934 versus investigator's choice in relapsed/refractory multiple myeloma
CTR20261732Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2934 in multiple myeloma (MM), sponsored by Nanjing Shunxin Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
TQB2934
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20261732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261732.